European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 2 , Pages 157-160 , December 2009

Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: Nelfinavir

  • Laurent Gavard

      Affiliations

    • Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France
    • Department of Obstetrics and Gynecology, AP-HP, Louis Mourier Hospital, University Denis Diderot Paris 7, Colombes, France
    • Corresponding Author InformationCorresponding author at: Faculté de Pharmacie – UPRES EA 2706, Laboratoire de Pharmacie Clinique, 5 rue Jean Baptiste Clément, 92296 Châtenay-Malabry cedex 20, France. Tel.: +33 01 4683 5577; fax: +33 01 4683 5618.
    • ,
  • Delphine Beghin

      Affiliations

    • Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France
    • ,
  • François Forestier

      Affiliations

    • Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France
    • ,
  • Yvon Cayre

      Affiliations

    • Robert Debré Hospital, AP-HP, University Pierre et Marie Curie - Paris 6, UMR 7613 Synthèse, Structure et Fonction de Molécules Bioactives, Paris, France
    • ,
  • Gilles Peytavin

      Affiliations

    • Department of Pharmacology, AP-HP, Bichat Hospital, University Denis Diderot - Paris 7, Paris, France
    • ,
  • Laurent Mandelbrot

      Affiliations

    • Department of Obstetrics and Gynecology, AP-HP, Louis Mourier Hospital, University Denis Diderot Paris 7, Colombes, France
    • ,
  • Robert Farinotti

      Affiliations

    • Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France
    • Department of pharmacology, AP-HP, Pitié-Salpêtrière Hospital, University Pierre et Marie Curie - Paris 6, Paris, France
    • ,
  • Sophie Gil

      Affiliations

    • Department of Clinical Pharmacy, University Paris-Sud 11, IFR141, School of Pharmacy, Châtenay-Malabry, France

Received 21 January 2009 ,Revised 1 July 2009 ,Accepted 18 August 2009.

References 

  1. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Rapport. 2008;132–172
  2. PHST Force. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available from: http://www.aidsinfo.nih.gov/.
  3. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449–473
  4. Hitti J, Andersen J, McComsey G, et al. Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084. Am J Obstet Gynecol. 2007;196(331):e1–e7
  5. Chappuy H, Treluyer JM, Rey E, et al. Maternal–fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2004;191:558–562
  6. Marzolini C, Kim RB. Placental transfer of antiretroviral drugs. Clin Pharmacol Ther. 2005;78:118–122
  7. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. Aids. 2006;20:1737–1743
  8. Hirt D, Urien S, Jullien V, et al. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples. Br J Clin Pharmacol. 2007;64:634–644
  9. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am J Obstet Gynecol. 1972;114:822–828
  10. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev. 1999;38:17–39
  11. Pacifici GM. Transfer of antivirals across the human placenta. Early Hum Dev. 2005;81:647–654
  12. Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol. 2008;198(433):e1–e2
  13. Myllynen P, Vahakangas K. An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. J Pharmacol Toxicol Methods. 2002;48:131–138
  14. Gavard L, Gil S, Peytavin G, et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol. 2006;195:296–301
  15. Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. Aids. 2002;16:889–893
  16. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002;21:835–838
  17. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. Maternal–fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol. 2001;185:178–181
  18. Lamotte C, Peytavin G, Farinotti R. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B Biomed Sci Appl. 1999;735:159–170
  19. Challier JC. Criteria for evaluating perfusion experiments and presentation of results. Contrib Gynecol Obstet. 1985;13:32–39
  20. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004;43:1071–1087
  21. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther. 2004;76:588–597
  22. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62:309–315
  23. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol. 2008;65:667–673
  24. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol. 2007;73:1573–1581
  25. Huisman MT, Smit JW, Crommentuyn KM, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids. 2002;16:2295–2301
  26. Sakurai AOY, Hirano H, Seigneuret M, et al. Quantitative structure–activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry. 2007;46:7678–7693
  27. Tanabe M, Nagata N, Inoue K, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137–1143
  28. Hirt D, Treluyer JM, Jullien V, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother. 2006;50:2079–2086

PII: S0301-2115(09)00496-5

doi: 10.1016/j.ejogrb.2009.08.007

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 147, Issue 2 , Pages 157-160 , December 2009

Article Tools

* Image Usage & Resolution